ArticleJournal of neuro-oncology2026
Prognostic role of delta radiomics in pediatric pontine diffuse midline gliomas.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePontine diffuse midline gliomas (PDMGs) are among the most lethal pediatric brain tumors with a median survival of approximately one year. Reliable prognostic markers are needed to guide treatment strategies and inform families. Our study aims to investigate the prognostic utility of delta-radiomic features in PDMGs. MATERIALS AND
methodsWe retrospectively analyzed 35 pediatric patients with PDMG diagnosed between 2012 and 2020, all treated with radiotherapy plus concomitant and adjuvant temozolomide. Pre- and post-treatment MRI (T1-weighted, T2-weighted, and ADC maps) were subjected to manual segmentation and texture feature extraction using MaZda software. Delta radiomics features were calculated as ratios between post- and pre-treatment values. Diagnostic performance for predicting survival below or above 12 months was assessed using ROC analysis, while overall survival was further evaluated with Kaplan–Meier and Cox regression models.
resultsMedian overall survival was 13 months (range: 6–69). Among baseline features, only sum average from non-contrast T1 was significant, with lower values (indicating higher heterogeneity) associated with shorter OS. In the post-radiotherapy setting, sum entropy from T1 images emerged as an independent prognostic predictor, with higher values correlating with longer OS. Delta radiomics parameters, particularly sum entropy derived from T1 and T2 sequences, yielded higher AUC values than single post-treatment features, suggesting superior prognostic accuracy.
conclusionOur preliminary results indicate that delta-radiomics outperforms static texture analysis in predicting overall survival in pediatric PDMGs, and to the best of our knowledge, this is the first study to investigate the prognostic utility of delta-radiomics in this population. Evidence is provided that delta radiomics can serve as a non-invasive marker for early prognostic stratification in pediatric PDMGs. Validation in larger, multi-center cohorts is required to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.